Crispr Therapeutics AG (CRSP) Stock Price Today
Aura AI Summary
Key Stats
- $4.97BMarket Cap
- -Volume
- HealthSector
- $76.7852W High
- $44.3452W Low
- -Typical Hold Time
- $3.32BEnterprise Value
- -Div Yield
- -Trading Activity
Track Crispr Therapeutics AG (CRSP) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Crispr Therapeutics AG has traded between a low of $44.34 and a high of $76.78, highlighting its annual price range. Buy and sell Crispr Therapeutics AG shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Most Recent News
Japanese firms use NVIDIA Nemotron to build AI tailored for local industries and workforce needs.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
Tech and industrial giants drive strong Q2 growth with major revenue and income gains.
In Q2 2026, top contributors to growth included Taiwan Semiconductor Manufacturing, Alphabet, United Rentals, Apple, and Visa. Alphabet’s Google Search and Cloud segments showed robust revenue growth of 19% and 63%, respectively, boosting operating i...
ARCpoint delays annual financial filings due to funding issues, expects to file by Sept 29, 2026.
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.